Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

A clinical study of mycophenolate mofetil combined with low-dose steroids in the management of pediatric systemic lupus erythematosus

Qiming Pang, Bangtao Li, Bo Ding, Shuo Gu, Jiaoyang Li, Suli Zhang

Hainan Women and Children’s Medical Center, Haikou, China;

For correspondence:- Suli Zhang Email: 69704936@qq.com Tel:+8618678186209

Accepted: 13 May 2022 Published: 30 June 2022

Citation: Pang Q, Li B, Ding B, Gu S, Li J, Zhang S. A clinical study of mycophenolate mofetil combined with low-dose steroids in the management of pediatric systemic lupus erythematosus. Trop J Pharm Res 2022; 21(6):1287-1294 doi: 10.4314/tjpr.v21i6.22

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the efficacy and safety of mycophenolate mofetil (MMF) combined with low-dose steroids in the treatment of pediatric systemic lupus erythematosus (pSLE).

Methods: A total of 76 children were diagnosed and admitted with SLE, lupus nephritis (LN) and type IV diffuse proliferative glomerulonephritis at Hainan Women and Children’s Medical Center, Haikou, China from March 2017 to December 2018, had their clinical data analyzed retrospectively. Among them, 38 children received methylprednisolone pulse combined with MMF and intermittent oral low-dose glucocorticoids (GC), labelled MMF group, while the remaining 38 children, which served as control group, were treated with oral GC and transitional reduction. Pertinent biochemical parameters were evaluated

Results: Compared with control group, MMF group showed a notably lower level of erythrocyte sedimentation rate (ESR), a higher level of complement C3, lower level of serum creatinine (Scr) and 24-h urine protein level 6 months after treatment (p < 0.05). Albumin level was higher in MMF group at 6 months and 12 months after treatment than in the control group. Compared to control group, the SLEDAI score in MMF group was significantly lower at 6 months and 12 months after treatment (p < 0.05). Body mass index, triglyceride, fasting blood glucose and intraocular pressure levels in the MMF group were significantly lower than those in the control group (p < 0.05). Post-treatment, peripheral blood CD3⁺ and CD4⁺ T lymphocytes, CD4⁺/CD8⁺ ratio and NK cell levels in the two groups were significantly increased, while CD8⁺ T lymphocyte level declined.

Conclusion: MMF combined with low-dose methylprednisolone controls symptoms early and mitigates renal injury in the treatment of pSLE. It is also safe, and effectively regulates the patient's cellular immune function.

Keywords: Mycophenolate mofetil, Methylprednisolone, Proliferative glomerulonephritis, Lupus nephritis, Systemic lupus erythematosus, SLEDAI score